English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 76923/106857 (72%)
造訪人次 : 19730559      線上人數 : 485
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://nccur.lib.nccu.edu.tw/handle/140.119/111651


    題名: Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial
    作者: Chen, Kuan-Yang;Lin, Tsung-Jung;Lin, Chin-Lin;Lee, Hsi-Chang;Wang, Chung-Kwe;Wu, Deng-Chyang
    陳冠仰
    貢獻者: 神經科學研究所
    關鍵詞: amoxicillin;clarithromycin;metronidazole;rabeprazole;urea c 13;amoxicillin;antiinfective agent;clarithromycin;metronidazole;proton pump inhibitor;rabeprazole;abdominal pain;adult;anorexia;antibiotic resistance;Article;bacterium culture;bitter taste;breath analysis;constipation;controlled study;diarrhea;dizziness;drug efficacy;drug treatment failure;endoscopy;eradication therapy;fatigue;female;follow up;headache;Helicobacter infection;Helicobacter pylori;histology;human;hybrid therapy;intention to treat analysis;major clinical study;male;medication compliance;nausea;patient compliance;prospective study;randomized controlled trial;rapid urease test;rash;risk factor;sequential therapy;side effect;Taiwan;treatment duration;treatment outcome;vomiting;aged;combination drug therapy;comparative study;drug effects;Helicobacter Infections;Helicobacter pylori;microbiology;middle aged;time factor;Adult;Aged;Amoxicillin;Anti-Bacterial Agents;Clarithromycin;Drug Therapy, Combination;Female;Helicobacter Infections;Helicobacter pylori;Humans;Intention to Treat Analysis;Male;Metronidazole;Middle Aged;Prospective Studies;Proton Pump Inhibitors;Rabeprazole;Taiwan;Time Factors;Treatment Outcome
    日期: 2015-09
    上傳時間: 2017-08-07 17:41:18 (UTC+8)
    摘要: AIM: To evaluate the efficacy of sequential vs hybrid therapy in patients with Helicobacter pylori (H. pylori ) infection. METHODS: From March 2013 to May 2014, one hundred and seventy-five H. pylori infected patients who had not been treated for H. pylori before were randomized to receive either sequential therapy (rabeprazole 20 mg and amoxicillin 1 g twice daily for 5 d, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 5 d) or hybrid therapy (rabeprazole 20 mg and amoxicillin 1 g for 7 d, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 d). H. pylori status was confirmed by positive results of both rapid urease test and histology examination or a positive result of culture. Eradication efficacy was assessed by follow-up endoscopy with rapid urease test and histological examination 8 wk after the end of anti-H. pylori therapy, or 13C-urea breath test at least 4 wk after completion of treatment. The primary outcome was H. pylori eradication by intension-to-treat (ITT) and per-protocol (PP) analyses. RESULTS: One hundred and sixty-seven patients (83 patients in the sequential group and 84 patients in the hybrid group) completed the study. The compliance rates were 97.6% and 97.7% for the two groups, respectively. The eradication rate was 78.2% for the sequential group and 92% for the hybrid group by ITT analysis (p = 0.01). The eradication rate was 81.9% for the sequential group and 96.4% for the hybrid group by PP analysis (p = 0.01). Univariate analysis for the clinical and bacterial factors did not identify any risk factors associated with treatment failure. Severe adverse events were observed in 2.3% of patients in the sequential group and 2.4% of those in the hybrid group. CONCLUSION: Due to a grade A (> 95%) success rate for H. pylori eradication by PP analysis, similar compliance and adverse events, hybrid therapy seems to be an appropriate eradication regimen in Taiwan. © The Author(s) 2015.
    關聯: World Journal of Gastroenterology, 21(36), 10435-10442
    資料類型: article
    DOI: http://dx.doi.org/10.3748/wjg.v21.i36.10435
    顯示於類別:[神經科學研究所 ] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    WJG-21-10435.pdf1041KbAdobe PDF66檢視/開啟


    在政大典藏中所有的資料項目都受到原著作權保護.


    社群 sharing

    著作權政策宣告
    1.本網站之數位內容為國立政治大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,惟仍請適度,合理使用本網站之內容,以尊重著作權人之權益。商業上之利用,則請先取得著作權人之授權。
    2.本網站之製作,已盡力防止侵害著作權人之權益,如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員(nccur@nccu.edu.tw),維護人員將立即採取移除該數位著作等補救措施。
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋